Recent developments in weekly paclitaxel therapy in lung cancer

Area of Science:

• Oncology
• Pharmacology
• Radiation Oncology

Background:

• Paclitaxel's administration schedule significantly impacts its toxicity and therapeutic effectiveness.
• Early weekly schedules were developed to enhance radiation synergy.
• Subsequent research focused on optimizing weekly paclitaxel without radiation to minimize side effects.

Purpose of the Study:

• To review the evolution of paclitaxel dosing and scheduling.
• To highlight the development of different weekly paclitaxel schedules.
• To discuss ongoing investigations into paclitaxel's efficacy and combination therapies.

Main Methods:

• Review of clinical studies and literature on paclitaxel administration.
• Analysis of schedule-dependent toxicity and therapeutic index.
• Identification of emerged weekly paclitaxel schedules.

Main Results:

• Three distinct weekly paclitaxel schedules have been established: 50 mg/m(2)/wk with concurrent radiation, 80-90 mg/m(2)/wk dose-dense without radiation, and 150-175 mg/m(2)/wk dose-intensive without radiation.
• Schedule modifications aim to improve the therapeutic index by managing toxicity.
• Efficacy and combination treatment roles are under extensive investigation.

Conclusions:

• Paclitaxel scheduling is a critical factor in optimizing cancer treatment.
• Ongoing research continues to refine paclitaxel's role in various oncological settings.
• Further studies are essential to fully understand the integration of these schedules with other therapies.